Tezspire Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing prevalence of severe asthma, advancements in monoclonal antibody development, growing biologics adoption in respiratory medicine, expansion of specialty respiratory clinics, improved diagnostic classification of asthma phenotypes.

The growth in the forecast period can be attributed to expansion of biologic indications, increasing demand for personalized respiratory therapies, rising investments in immunology drug development, growing focus on early intervention strategies, expansion of advanced asthma treatment guidelines. Major trends in the forecast period include increasing adoption of targeted biologic therapies, rising use of tslp inhibitors in respiratory care, growing focus on severe asthma management, expansion of biologic treatment pipelines, enhanced emphasis on precision immunology.

The rising prevalence of asthma is expected to drive the growth of the Tezspire market going forward. Asthma is a chronic respiratory disease marked by inflammation and narrowing of the airways, causing symptoms such as wheezing, coughing, shortness of breath, and difficulty breathing. The increasing prevalence of asthma is linked to factors such as environmental pollution, lifestyle changes, and greater exposure to allergens and respiratory irritants. Tezspire is a targeted biologic therapy that helps manage severe asthma by inhibiting a key protein involved in airway inflammation, reducing exacerbations, and offering relief for patients unresponsive to standard treatments. For instance, in October 2024, the National Asthma Council, an Australia-based non-profit organization, reported that in 2023, there were 474 asthma-related deaths in Australia - 325 females and 149 males - nearly identical to the 473 deaths recorded in 2022, indicating a persistent trend in asthma-related mortality. Therefore, the rising prevalence of asthma is driving growth in the Tezspire market.

The increasing number of clinical trials is expected to further propel the Tezspire market. Clinical trials are structured research studies involving human participants to evaluate the safety, effectiveness, and potential side effects of medical treatments or interventions. The growth in clinical trials is driven by advancements in medical research, demand for personalized therapies, and the need to assess novel treatments for emerging health conditions. Clinical trials have been crucial in demonstrating Tezspire’s safety and efficacy, supporting its approval for severe asthma and encouraging its adoption in clinical practice. For example, in December 2024, the Association of the British Pharmaceutical Industry (ABPI), a UK-based trade association, reported that industry-sponsored clinical trials initiated in the UK increased from 411 in 2022 to 426 in 2023. Therefore, the rise in clinical trials is driving the growth of the Tezspire market.

Key companies in the Tezspire market are focusing on obtaining regulatory approvals for broader indications, especially for asthma and other chronic inflammatory conditions. Regulatory approvals are formal authorizations from health authorities, such as the FDA or EMA, confirming that a drug meets safety, efficacy, and quality standards for marketing and use. For instance, in February 2023, AstraZeneca plc, a UK-based pharmaceutical company, received approval for Tezspire (tezepelumab-ekko) for self-administration via a pre-filled pen for patients aged 12 and older with severe asthma, in collaboration with Amgen Inc., a US-based biotechnology company. This approval allows patients to administer the therapy at home following proper training. Supported by the PATHFINDER clinical trial program, which showed a high success rate of self-administration among participants, Tezspire is notable as the first biologic for severe asthma without limitations based on phenotype or biomarker status, offering a wider treatment option for patients.

Major companies operating in the tezspire market are AstraZeneca plc, Amgen Inc.

North America was the largest region in the tezspire market in 2025. The regions covered in the tezspire market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tezspire market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the tezspire market by increasing costs associated with imported biologic manufacturing equipment, cold-chain storage systems, sterile injectables packaging, and advanced formulation inputs. North America and Europe are most affected due to reliance on global biologics supply chains and specialized production facilities. These tariffs are raising distribution and commercialization costs for biologic therapies. However, they are also encouraging regional biologics manufacturing expansion, domestic fill-finish investments, and localized supply chain optimization.

The tezspire market research report is one of a series of new reports that provides tezspire market statistics, including tezspire industry global market size, regional shares, competitors with a tezspire market share, detailed tezspire market segments, market trends and opportunities, and any further data you may need to thrive in the tezspire industry. This tezspire market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tezspire is a biologic therapy that targets and inhibits thymic stromal lymphopoietin (TSLP), a protein involved in the inflammatory processes of respiratory diseases. It is used to treat severe asthma and chronic obstructive pulmonary disease (COPD), helping to reduce inflammation and improve breathing.

The primary indications for Tezspire include asthma, chronic obstructive pulmonary disease, chronic rhinosinusitis, chronic spontaneous urticaria, and eosinophilic esophagitis. Asthma is a chronic condition characterized by airway inflammation and narrowing, which makes breathing difficult. Tezspire is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used by end users including adult and pediatric patients.

The tezspire market consists of the sales of monoclonal antibodies (mAbs), vaccines, and fusion proteins. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.